Short Interest in DBV Technologies S.A. (NASDAQ:DBVT) Decreases By 71.2%

DBV Technologies S.A. (NASDAQ:DBVT) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 161,900 shares, a drop of 71.2% from the March 31st total of 561,900 shares. Approximately 0.6% of the shares of the stock are short sold. Based on an average daily volume of 395,800 shares, the short-interest ratio is presently 0.4 days.

DBV Technologies Stock Performance

Shares of DBVT traded up $0.78 on Monday, reaching $9.31. The stock had a trading volume of 42,996 shares, compared to its average volume of 183,330. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $9.60. The firm has a market capitalization of $255.00 million, a price-to-earnings ratio of -2.08 and a beta of -0.08. The company has a 50-day simple moving average of $5.91 and a 200-day simple moving average of $4.48.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The business had revenue of $0.51 million during the quarter. On average, analysts expect that DBV Technologies will post -7.05 EPS for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission. 71.74% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on DBVT. JMP Securities reissued a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a report on Friday, January 10th. StockNews.com assumed coverage on shares of DBV Technologies in a report on Wednesday, April 23rd. They set a “hold” rating for the company.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.